Loading
More than 99% of the smallest, lowest-grade precursor lesions in the pancreas already carry a mutation in KRAS, CDKN2A, GNAS or BRAF, showing the genetic change comes first.
More than 99% of the earliest-stage, lowest-grade pancreatic intraepithelial neoplasm-1 lesions were shown to contain mutations in KRAS, p16/CDKN2A, GNAS or BRAF.
It fixes the order of events, with the initiating mutation present in the smallest visible lesion, and it warns that finding mutant KRAS in a duct does not mean cancer.
Shares Anirban Maitra, GNAS, Bert Vogelstein, Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors.
Shares Gastroenterology, GNAS, Bert Vogelstein, CDKN2A.
Shares Gastroenterology, GNAS, Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, KRAS.
Shares GNAS, Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Pancreatic ductal adenocarcinoma.
Shares Anirban Maitra, Bert Vogelstein, CDKN2A, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center.
Shares GNAS, Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, KRAS.
Shares Anirban Maitra, Gastroenterology, KRAS, Pancreatic ductal adenocarcinoma.
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Pancreatic ductal adenocarcinoma.